

PRODUCT INFORMATION


3TC[®] TABLETS AND ORAL SOLUTION

NAME OF THE MEDICINE:

Lamivudine

DESCRIPTION:

Chemically, lamivudine is the free base of (2R-cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, and has the following structural formula:



The molecular formula of lamivudine is C₈H₁₁N₃O₃S and it has a relative molecular mass of 229.3.

Lamivudine is a white to off-white crystalline solid which is highly soluble in water.

CAS REGISTRY NUMBER: 134678-17-4

PHARMACOLOGY:

Mode of Action: Lamivudine (3TC[®]) is a potent, selective inhibitor of HIV-1 and HIV-2 replication *in vitro*. It is also active against zidovudine (Retrovir[®])-resistant clinical isolates of HIV.

In vitro, lamivudine demonstrates low cytotoxicity to peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage cell lines and to a variety of bone marrow progenitor cells. Lamivudine therefore has, *in vitro*, a high therapeutic index.

Lamivudine is metabolised intracellularly to the 5'-triphosphate which has an intracellular half-life of 10.5 - 15.5 hours. Lamivudine 5'-triphosphate is a weak inhibitor of the RNA and DNA dependent activities of HIV reverse transcriptase; its main mode of action is as a chain terminator of HIV reverse transcription.

Lamivudine does not interfere with cellular deoxynucleotide metabolism and has little effect on mammalian cell and mitochondrial DNA content.

The relationships between in vitro susceptibility of HIV to lamivudine and the clinical response to therapy remain under investigation. In vitro sensitivity testing has not been standardised and results may vary according to methodological factors.

Reduced in vitro sensitivity to lamivudine has been reported for HIV isolates from patients who have received lamivudine therapy.

Lamivudine has been shown to be usually but not always synergistic with zidovudine, inhibiting the replication of HIV in cell culture. Synergistic antiviral activity has also been demonstrated in vitro with a combination of lamivudine and the protease inhibitor saquinavir (Ro 31-8959) and in triple combination with zidovudine and didanosine.

In vitro studies show that restored sensitivity to zidovudine may occur following serial passage of zidovudine-resistant HIV-1 in increasing concentrations of lamivudine. Furthermore, in vivo, there is evidence showing that lamivudine plus zidovudine delays the emergence of zidovudine-resistant isolates in individuals with no prior anti-retroviral therapy.

Drug Resistance: Lamivudine-resistant isolates of HIV-1 have been selected in vitro. The resistant isolates showed reduced susceptibility to lamivudine and genotypic analysis showed that the resistance was due to specific substitution mutations in the HIV-1 reverse transcriptase at codon 184 from methionine to either isoleucine or valine. HIV-1 strains resistant to both lamivudine and zidovudine have been isolated.

Susceptibility of clinical isolates to lamivudine and zidovudine was monitored in controlled clinical trials. In patients receiving lamivudine monotherapy or combination therapy with lamivudine plus zidovudine, HIV-1 isolates from most patients became phenotypically and genotypically resistant to lamivudine within 12 weeks. In some patients harbouring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of mutations conferring resistance to zidovudine.

Cross-Resistance: Cross-resistance among certain reverse transcriptase inhibitors has been observed. Cross-resistance between lamivudine and zidovudine has not been reported. In some patients treated with lamivudine alone or in combination with zidovudine, isolates have emerged with a mutation at codon 184, which confers resistance to lamivudine. In the presence of the 184 mutation, cross-resistance to didanosine and zalcitabine has been seen in some patients; the clinical significance is unknown. In some patients treated with zidovudine plus didanosine or zalcitabine, isolates resistant to multiple reverse transcriptase inhibitors, including lamivudine, have emerged.

Pharmacokinetics:

Absorption:

Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85%. Following oral administration the mean time (t_{\max}) to maximal serum concentrations (C_{\max}) is about an hour. At therapeutic dose levels ie approximately 4 mg/kg/day (as 150 mg twice daily) C_{\max} is in the order of 1-1.9 $\mu\text{g/mL}$.

When a capsule formulation of lamivudine was ingested with food, there was a significant reduction in C_{\max} (47%) and extension to T_{\max} (2.2 hours). Although absorption of lamivudine was delayed, the amount of drug absorbed is not reduced.

The 150 mg tablet is bioequivalent and dose proportional to the 300 mg tablet with respect to AUC_{∞} , C_{\max} and t_{\max} .

The active moiety, intracellular lamivudine triphosphate, has a prolonged terminal half-life in the cell (10.5 to 15.5 hours) compared to the plasma lamivudine half-life (5 to 7 hours). In 60 healthy adult volunteers, 3TC 300 mg once daily has been demonstrated to be pharmacokinetically equivalent at steady-state to 3TC 150 mg twice daily with respect to intracellular triphosphate AUC_{24} and C_{\max} .

The mean intracellular lamivudine triphosphate $C_{0,ss}$ was reduced by 16% and the mean $C_{24,ss}$ was reduced by 19% in volunteers given lamivudine 300mg od compared with lamivudine 150mg bd. The clinical relevance of the lower C_{\min} is unknown.

A study compared the pharmacokinetics of lamivudine tablets 300mg once daily and lamivudine tablets 150mg twice daily in 60 healthy, fasted volunteers. Steady state plasma lamivudine AUCs were comparable for the two dosage regimens (mean ratio 0.94, 90% CI: 0.92 - 0.97) whereas the C_{\max} was increased by 66% (mean ratio 90% CI: 1.57 – 1.74) and C_{trough} was 53% lower (mean ratio 90% CI: 0.44 – 0.50) with the 300mg once daily. The clinical significance of the lower trough levels is unknown.

Administration of crushed tablets with a small amount of semi-solid food or liquid would not be expected to have an impact on the pharmaceutical quality, and would therefore not be expected to alter the clinical effect. This conclusion is based on physiochemical and pharmacokinetic data, assuming that the patient crushes and transfers 100% of the tablet and ingests immediately.

Distribution:

From intravenous studies, the mean volume of distribution is 1.3 L/kg and the mean terminal half-life of elimination is 5 to 7 hours.

Limited data shows lamivudine penetrates the into the central nervous system and reaches the cerebrospinal fluid. The mean ratio CSF/serum lamivudine concentration 2-4 hours after oral administration was approximately 0.12. The true extent of penetration or relationship with any clinical efficacy is unknown.

Metabolism:

Co-administration of zidovudine and lamivudine in a study of twelve asymptomatic patients with HIV caused minimal changes in lamivudine levels. The availability (mean AUC) of zidovudine was increased by 13%, mean C_{\max} was increased by 28%, and mean $t_{1/2}$ reduced by 11%. There was considerable individual variation and the changes were not statistically significant. The relevance of these changes to clinical efficacy and safety is not known.

The likelihood of adverse drug interactions with lamivudine is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged drug. An interaction with trimethoprim, a constituent of trimethoprim with sulphamethoxazole causes a 40% increase in lamivudine exposure at therapeutic doses.

Excretion:

The mean systemic clearance of lamivudine is approximately 0.32 L/kg/h, with predominantly renal clearance (>70%) via active tubular secretion, but little (<10%) hepatic metabolism.

A single dose pharmacokinetic study (n=16) in HIV-infected patients with normal renal function and with moderate (Clcr <30 mL/min and >10 mL/min) or end stage renal impairment (Clcr <10 mL/min) showed there was a linear relationship between lamivudine clearance and renal function. A dosage adjustment is required in patients with creatinine clearance below 50 mL/min (see **DOSAGE AND ADMINISTRATION**).

A single dose pharmacokinetic study (n = 24) in patients with moderate and severe hepatic impairment in comparison with healthy subjects showed no statistically significant differences for any of the mean pharmacokinetic parameters assessed. There was a trend towards reduced renal clearance in severely impaired subjects to an average of 76% (90% CI: 58% to 101%) relative to healthy control subjects.

Pharmacokinetics in children:

In general, lamivudine pharmacokinetics in paediatric patients are similar to adults. However, absolute bioavailability (approximately 55-65%) was reduced in paediatric patients below 12 years of age. In addition, systemic clearance values were greater in younger paediatric patients and decreased with age approaching adult values around 12 years of age. Recent findings indicate that exposure in children 2 to < 6 years of age may be reduced by about 30% compared with other age groups. Further data to support this conclusion are currently awaited. At present, the available data do not suggest that lamivudine is less efficacious in this age group.

There are limited pharmacokinetic data for patients less than three months of age. In neonates one week of age, lamivudine oral clearance was reduced when compared to paediatric patients and is likely to be due to immature renal function and variable absorption. Therefore, to achieve similar adult and paediatric exposure, for neonates a dose of 2mg/Kg should be considered. Glomerular filtration estimates suggests that to achieve similar adult and paediatric exposure, the recommended dose for children aged six weeks and older could be 4mg/kg twice a day. However there is no data available in neonates older than one week old.

CLINICAL TRIALS:**Clinical Endpoint Study:**

Clinical end-point data from a prospective study indicate that lamivudine in combination with zidovudine alone or in combination with zidovudine containing treatment regimens results in a significant reduction in the risk of disease progression and mortality.

NUCB3007 (CAESAR) was a multicenter, double-blind, placebo-controlled study comparing continued current therapy [zidovudine (AZT) alone (62% of patients) or zidovudine with didanosine (ddI) or zalcitabine (ddC) (38% of patients)] to the addition of 3TC or 3TC plus an investigational non-nucleoside reverse transcriptase inhibitor, randomised 1:2:1. A total of 1,840 HIV-infected adults with 25 to 250 (median, 126) CD4 cells/mm³ at baseline were enrolled: median age was 36 years, 87% were male, 83% were nucleoside-experienced, and

17% were therapy-naive. The median duration of treatment for each group was current therapy* 327 days, 3TC plus current therapy* 360 days and 3TC plus NNRTI** plus current therapy* 360 days. Results are summarised in Table 1.

Table 1: Number of Patients (%) With At Least One HIV Disease Progression Event or Death - Intention to Treat Population

Endpoint	Current Therapy* (n = 471)	3TC plus Current Therapy* (n = 907)	3TC plus a NNRTI** plus Current Therapy* (n = 462)
HIV progression or death	95 (20%)	86 (9%) [†]	42 (9%)
Death	28 (6%)	23 (3%) [‡]	14 (3%)

*Current treatment = AZT (200 mg tds or 250 mg bd) monotherapy, AZT + ddI (250 mg bd) or AZT + ddC (0.75 mg tds).

**An investigational non-nucleoside reverse transcriptase inhibitor not approved in the Australia.

[†] p<0.0001 for 3TC + current therapy vs current therapy alone.

[‡] p= 0.0007 for 3TC + current therapy vs current therapy alone.

The data showed there was a significant reduction in progression to the combined endpoint of a new AIDS event or death for patients who received lamivudine in combination with zidovudine containing regimens compared to patients maintained on zidovudine containing regimens alone (p<0.0001). The Hazard Ratio (HR) was 0.427 (95% confidence interval 0.318 - 0.572), or a 57% reduction in risk. In addition, the data indicated a significant reduction in death, regardless of causality, in the combination lamivudine plus zidovudine containing regimens as compared to the zidovudine containing regimens alone (p=0.0007); HR = 0.399 (95% CI 0.230-0.693) or a 60% reduction in risk.

ACTG320 was a randomised, double-blind, placebo-controlled study to compare indinavir, zidovudine (or stavudine) and lamivudine with the 2 drug regimen of zidovudine (or stavudine) and lamivudine in HIV-infected patients with CD4 counts ≤ 200 cells/mm³. Patients had received ≥ 3 months prior zidovudine therapy and had no prior exposure to protease inhibitors. A total of 1156 patients were randomised. The median duration of follow-up was 38 weeks. During the study there were 96 new AIDS-defining events or deaths, 63 (11%) in the zidovudine/lamivudine arm and 33 (6%) in the zidovudine/lamivudine/indinavir arm (estimated Hazard Ratio 0.50). There were 13 (6%) deaths in the zidovudine/lamivudine arm and 5 (2%) in the zidovudine/lamivudine/indinavir arm (Hazard Ratio 0.37). Both these results were statistically significant.

Surrogate Endpoint Studies in adults:

Clinical efficacy in adults was based on the results of four pivotal studies in patients with or without prior antiretroviral therapy. Study designs are summarised in Table 2. All were randomised, double blind, multicentre studies. The characteristics of the patients at baseline are given in Table 3.

Table 2 - Summary of pivotal efficacy studies in adults

Study design - Pivotal studies in adults					Summary of results			
					0-24 weeks		0-52 weeks	
					Mean time-weighted change		52 week change from baseline	
Report No (Protocol)	Study Design Patients	Treatment doses	Number randomised	Duration of treatment	CD4	Log 10 HIV RNA	CD4	Log 10 HIV RNA
UCR/95/002 (NUCA3001)	DB, MC Zdv-naive CD4 200-500	Lam 300mg bd	87	24 weeks DB	24	-0.59	-11	-0.32
		Zdv 200mg tds	93	DB continuation	17	-0.31	-53	-0.14
		Zdv + Lam 150mg	92		55	-1.12	61	-0.80
		Zdv + Lam 300mg	94		45	-1.15	60	-1.04
UCR/95/003 (NUCA3002)	DB, MC Zdv-experienced CD4 100-300	Zdv + ddC 0.75mg	86	24 weeks DB	-2	-0.66	16	-0.50
		Zdv + Lam 150mg	84	DB continuation	38	-0.80	35	-0.48
		Zdv + Lam 300mg	84		39	-0.91	27	-0.55
GIO/94/003 (NUCB3001)	DB, MC Zdv-naive CD4 100-400	Zdv 200mg tds	64	24 weeks DB	18	-0.57		
		Zdv + Lam 300mg	65	OL continuation	75	-1.33		
GIO/94/005 (NUCB3002)	DB, MC Zdv-experienced CD4 100-400	Zdv 200mg tds	73	24 weeks DB	-18	-0.07		
		Zdv + Lam 150mg	75	OL continuation	38	-0.96		
		Zdv + Lam 300mg	75		32	-0.77		


Zidovudine given at a dose of 200mg tds in all studies. Lamivudine dosed bd in all studies.

Table 3 - Characteristics of patients randomised to pivotal studies

	NUCA3001	NUCA3002	NUCB3001	NUCB3002
Number of patients	366	254	129	223
Age (median) years	34	37	33	36
Asymptomatic HIV infection	80%	58%	64%	53%
Duration of prior antiretroviral therapy (months)	<1	24	<1	23
baseline CD4 cells/mm ³ (median)	200 to 500 (352)	100 to 300 (211)	100 to 400 (260)	100 to 400 (241)

After 24 weeks: In zidovudine-naive patients the combination of lamivudine and zidovudine resulted in a highly significant ($p < 0.001$) increase in absolute CD4 cell count and reduction in \log_{10} HIV RNA relative to zidovudine monotherapy (600 mg/day) or lamivudine monotherapy (600 mg/day). Similarly, in zidovudine-experienced patients, the combination of lamivudine and zidovudine resulted in significantly greater improvements in CD4 cell count than either zidovudine monotherapy (600 mg/day) or a combination of zidovudine and zalcitabine (600 mg/day + 0.75 mg) and a significantly greater reduction in \log_{10} HIV-RNA than zidovudine monotherapy.

In the North American studies (NUCA3001 and NUCA3002) patients were allowed to remain in the study with blinding intact until the last patient had completed the 24 week assessment. Analysis of the subset of patients receiving treatment for at least 52 weeks established that the clinical benefits on CD4 cell count and viral load were maintained compared to zidovudine monotherapy over this period ($p < 0.001$). Results for CD4 count and \log_{10} HIV-RNA are given in figure 1.



Once Daily Dosing

EPV 20001 was a randomised, double-blind, controlled, multicentre study to evaluate the efficacy and safety of lamivudine 300mg once daily vs. lamivudine 150mg bid, as a component of triple therapy, in antiretroviral-naïve adults with HIV-1 infection.

The proportions of subjects with plasma HIV-1 RNA <400copies/mL for Intention-to-Treat Population using missing = failure analysis are summarised in the table 4:

Table 4: Summary of proportion of subjects with plasma HIV-1 RNA <400 copies/mL:

Week	3TC Dose Group		95 % Confidence Interval
	OD N=278 % (n)	BID N=276 % (n)	
Week 4	53% (148)	52% (144)	(-7.7, 7.3)
Week 8	67% (187)	72% (199)	
Week 12	74% (207)	78% (216)	
Week 16	75% (208)	75% (207)	
Week 20	71% (196)	75% (207)	
Week 24	72% (199)	72% (198)	

The data demonstrate that the proportion of patients with plasma HIV-1 RNA <400 copies/mL at week 24 did not differ between treatment groups (od: 72%; bid: 72%). While the subjects in the od group had a baseline plasma HIV-1 RNA level $0.8\log_{10}$ copies/ml higher than those of the bid group (od: $5.1\log_{10}$ copies/ml; bid: $4.3\log_{10}$ copies/ml), the two groups were comparable with respect to on-treatment plasma HIV-1 RNA response. Twenty-nine (5%) of subjects had virological failure by week 24 but virus for resistance testing could only be isolated from 22 samples (11 subjects in each arm); the incidence of resistance was comparable in the treatment arms.

Median CD4+ cell count values and changes from baseline are summarised by treatment group in table 5.

Table 5: Median CD4+ cell and change from baseline (cells/mm³)

Week	Median CD4+ Count Median (range, n)		Median Change from baseline Median (range, n)	
	3TC Dose Group		3TC Dose Group	
	3TC OD N=278	3TC BID N=276	3TC OD N=278	3TC BID N=276
Baseline	340 (69-945, 278)	386 (90-1089, 276)	--	--
Week 12	432 (90-1357, 233)	477 (53-1383, 234)	95 (-300-605, 233)	85 (-475-721, 234)
Week 24	475 (123-1301, 209)	518 (105-1497, 212)	128 (-289-687, 209)	123 (-290-518, 212)

The data demonstrate that there were similar increases in median CD4+ cell counts observed between 3TC treatment groups at week 24 (OD: 128cells/mm³; BID: 123cells/mm³)

The results for Study EPV 20001 are reported to 24 weeks; this study is currently ongoing.

EPV40001 was a small, randomised, open label, controlled multicentre study in Thailand to evaluate the efficacy and safety of lamivudine (3TC) once daily (OAD) versus 3TC BID and abacavir (ABC) once daily versus ABC BID as components of a combination regimen including zidovudine (ZDV), 3TC and ABC in antiretroviral-naïve, HIV-1 infected adults. Subjects were randomised to receive ZDV/3TC (BID)/ABC (BID) (control group), ZDV /3TC (OAD) / ABC (BID) or ZDV/3TC (BID)/ABC (OAD).

The three groups showed comparable efficacy using AAUCMB (Average Area Under Curve Minus Baseline) for HIV-1 RNA at week 48, the primary efficacy parameter for establishing non-inferiority with a confidence interval of $0.4 \log_{10}$ copies/ml ($-2.0 \log_{10}$ copies/ml control

group, $-2.0 \log_{10}$ copies/ml 3TC OAD group, $-1.9 \log_{10}$ copies/ml ABC OAD group) in the Intent to Treat Exposed population (ITTE).

Using a secondary parameter of efficacy, the proportions of subjects with plasma HIV-1 RNA <400 copies/ml for the ITTE population in a missing = failure analysis are summarised in table 6:

Table 6: Summary of proportion of subjects with HIV-1 RNA <400 copies/ml

Week	Control Group (n = 50)	<u>Treatment Group</u>	
		3TC OAD (n = 50)	ABC OAD (n = 51)
4	62% (31)	62% (31)	59% (30)
12	84% (42)	76% (38)	76% (39)
24	84% (42)	70% (35)	71% (36)
48	78% (39)	66% (33)	63% (32)

Although there was a small numerical difference in treatment response in favour of the control group, this difference was primarily driven by a slightly higher incidence of treatment discontinuations in the OAD arms for reasons other than virological failure. Fifteen (10%) subjects had virological failure associated with resistance mutations; the incidence was comparable in the treatment arms.

There were similar increases in median CD4+ cell counts observed in the three treatment groups at week 48 (control group: +216 cells/mm³; 3TC OAD: +166 cells/mm³; ABC OAD: +152 cells/mm³).

Studies in children:

Pharmacokinetic studies in children have established that relatively higher doses are required (8 mg/kg/day) to achieve comparable clinical exposure to that obtained with the recommended dose in adults (see **PHARMACOKINETICS** and **DOSAGE AND ADMINISTRATION**).

An open label, dose-escalation study (lamivudine monotherapy) was conducted in children aged 3 months to 17 years who had received no or minimal anti-retroviral therapy (Arm A) or had experienced toxicity or become refractory to prior antiretroviral therapy (Arm B). At one centre compassionate treatment of patients with recurrent opportunistic infections was also allowed (Arm C). Patients were dosed at 1, 2, 4, 8, 12 or 20 mg/kg/day in two divided doses for 24 weeks. Dose escalation/reduction to 8mg/kg/day was allowed after 24 weeks of treatment.

Lamivudine showed evidence of antiviral activity in both naive (Arm A) and experienced (Arm B) patients but no consistent dose-response effects. The combined results for all dose levels in both groups are given in Table 7. No efficacy data are available on patients in Arm C.

Table 7 - Combined results for all dose levels in both groups

GROUP	Arm A		Arm B	
Patients	18		71	
Age (range)	3 months to 19 years		3 months to 19 years	
Age (median)	3.7 years		8.4 years	
CDC class P1	67%			
CDC class P2			97%	
RESULTS	Baseline	Change at Week 24 ¹	Baseline	Change at Week 24 ¹
CD4 count (/mm ³)	697	24	82	4
Log ₁₀ HIV-RNA (copies/mL) ²	4.4	-0.2	4.9	-0.2

¹ Median changes from baseline through week 24

² Subset of patients with >1000 copies/mL at baseline

The peak increase in CD4 count was 104 cells/mm³ at week 4 in Arm A and 6 cells/mm³ in Arm B. CD4 counts were maintained at or close to baseline values in both arms of the study to week 48. Serum HIV-1-RNA concentrations decreased during the same period and for the subset of patients with >1000 copies/mL at baseline was significantly different to baseline in Arm A at week 48 (-0.7 log₁₀, p=0.031), and in Arm B at week 12 (-0.2 log₁₀, p=0.009), week 24 (-0.2 log₁₀, p=0.008) and week 48 (0.2 log₁₀, p=0.032)

ACTG300 was a multicentre randomized double-blind study, in paediatric patients, that provided for comparison of lamivudine plus zidovudine to didanosine monotherapy. The median duration on study medication was 10.1 months for patients receiving lamivudine + zidovudine and 9.2 months for children receiving didanosine monotherapy. Table 8 provides details of the changes from baseline for the two treatment groups and Table 9 the number of patients reaching primary clinical endpoint (disease progression or death):

Table 8 – Results from Study ACTCG300

	ZDV/LAM		ddl	
Patients	236		236	
Age in years (median)	2.7		2.8	
CDC Category				
N: no signs/symptoms	35 (15%)		34 (14%)	
A: mild signs/symptoms	116 (49%)		105 (44%)	
B: moderate signs/symptoms	50 (21%)		65 (28%)	
C: Severe signs/symptoms	35 (15%)		32 (14%)	
Results	Baseline	Change from baseline ¹	Baseline	Change from baseline ¹
Median HIV-1 RNA (log ₁₀ copies/mL)	5.1	-0.6 ²	5.1	-0.4 ²
CD4 (cells/mL)	703.0	94.0 ²	658.5	0.0 ²

1: Median changes from baseline through to week 36.

2: Statistically significant difference

Table 9: Number of Patients (%) Reaching a Primary Clinical Endpoint (Disease Progression or Death)

Endpoint	EPIVIR plus RETROVIR (n = 236)	Didanosine (n = 236)
HIV disease progression or death (total)	15 (6.4%)	39 (17%)
Physical growth failure	7 (3.0%)	7 (3%)
Central nervous system deterioration	4 (1.7%)	12 (5.1%)
CDC Clinical Category C	2 (0.8%)	8 (3.4%)
Death	2 (1%)	12(5%)

This study demonstrated a significant benefit of combination zidovudine/lamivudine therapy over didanosine monotherapy by clinical and laboratory measures.

There are no studies of the safety and efficacy of lamivudine administered once daily in children

INDICATIONS:

3TC (lamivudine) in combination with other antiretroviral agents is indicated for the treatment of HIV infected adults and children.

CONTRAINDICATIONS:

The use of lamivudine is contra-indicated in patients with known hypersensitivity to lamivudine or to any ingredient of the preparation.

PRECAUTIONS:

Use with caution in the following circumstances:

Pancreatitis in paediatric patients: In paediatric patients with a history of pancreatitis or other significant risk factors for the development of pancreatitis, lamivudine should be used with extreme caution and only if there is no satisfactory alternative therapy. Treatment with lamivudine should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur (see **ADVERSE EFFECTS**).

Renal Impairment: In patients with moderate to severe renal impairment, the terminal plasma half-life of lamivudine exposure is increased due to decreased clearance. The dose should be adjusted (see **DOSAGE AND ADMINISTRATION**).

Cirrhotic liver disease/Hepatitis B virus: Clinical trial and marketed use of lamivudine, have shown that some patients with chronic hepatitis B virus (HBV) disease may experience clinical or laboratory evidence of recurrent hepatitis upon discontinuation of lamivudine, which may have more severe consequences in patients with decompensated liver disease. If

lamivudine is discontinued in a patient with HIV and HBV coinfection, periodic monitoring of both liver function tests and markers of HBV replication should be considered.

Fat Redistribution: Redistribution / accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, elevated serum lipid and blood glucose levels have been observed either separately or together in some patients receiving combination antiretroviral therapy (see ADVERSE EFFECTS).

Whilst all members of the PI and NRTI classes of medicinal products have been associated with one or more of these specific adverse events, linked to a general syndrome commonly referred to as lipodystrophy, data indicate that there are differences in the risk between individual members of the respective therapeutic classes.

In addition, the lipodystrophy syndrome has a multi-factorial aetiology; with for example HIV disease status, older age and duration of antiretroviral treatment all playing important, possibly synergistic roles.

The long-term consequences of these events are currently unknown.

*Clinical examination should include evaluation for physical signs of fat redistribution. Consideration should be given to the measurement of serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.

Lactic acidosis and severe hepatomegaly with steatosis: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues either alone or in combination, including lamivudine. A majority of these cases have been in women.

Clinical features which may be indicative of the development of lactic acidosis include generalised weakness, anorexia, and sudden unexplained weight loss, gastrointestinal symptoms and respiratory symptoms (dyspnoea and tachypnoea).

Caution should be exercised when administering lamivudine to any patient, and particularly to those with known risk factors for liver disease. Treatment with lamivudine should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

Immune Reconstitution Syndrome:

In HIV-infected patients with severe immune deficiency at the time of initiation of anti-retroviral therapy (ART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of ART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and *Pneumocystis jirovecii* (*P. carinii*) pneumonia. Any inflammatory symptoms must be evaluated without delay and treatment initiated when necessary. Autoimmune disorders (such as Graves' disease, polymyositis and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however the time to onset is more variable, and can occur many months after initiation of treatment and sometimes can be an atypical presentation.

Diabetes (oral solution only): Diabetic patients should be advised that an adult dose of oral solution contains 3 g of sucrose.

Carcinogenicity mutagenicity:

When lamivudine was administered orally to separate groups of rodents at doses up to 2000 times (mice and male rats) and 3000 (female rats) mg/kg/day, there was no evidence of a carcinogenic effect due to lamivudine in the mouse study. In the rat study there was an increased incidence of endometrial tumours at the highest dose (approximately 70 times the estimated human exposure at the recommended therapeutic dose of one tablet twice daily, based on AUC). However, the relationship of this increase to treatment is uncertain.

Lamivudine was not mutagenic in *Salmonella typhimurium* or *E. coli* reverse mutation assays with and without metabolic activation but did induce mutations at the thymidine kinase locus of the mouse lymphoma L5178Y cells without metabolic activation and was clastogenic in human peripheral blood lymphocytes, with and without metabolic activation *in vitro*. In rats lamivudine did not cause chromosomal damage in bone marrow cells *in vivo* or cause DNA damage in primary hepatocytes at estimated exposures many times higher than those observed clinically.

Lamivudine should not represent a genotoxic hazard to patients undergoing treatment.

Effects on fertility:

No evidence of impaired fertility was seen in rats with exposures (based on C_{max}) up to 70 times those observed at the clinical dosage.

Use in Pregnancy: Pregnancy category B3

There is limited data available on the safety of lamivudine in human pregnancy. Studies in humans have confirmed that lamivudine crosses the placenta. Use in pregnancy should be considered only if the benefit outweighs the risk.

No evidence of teratogenicity was observed in rats and rabbits with exposure (based on C_{max}) up to 40 and 36 times respectively those observed in humans at the clinical dosage. However, embryoletality was increased with consequent reduction in litter size in rabbits at exposures (based on both C_{max} and AUC values) of less than those observed at the clinical dosage of 150 mg bd (approximately 4 mg/kg).

Lamivudine crossed the placenta in rats and rabbits. The significance of increased embryoletality seen in animal studies is uncertain in humans.

There have been reports of mild, transient elevations in serum lactate levels, which may be due to mitochondrial dysfunction, in neonates and infants exposed in utero or peri-partum to nucleoside reverse transcriptase inhibitors (NRTIs). The clinical relevance of transient elevations in serum lactate is unknown. There have also been very rare reports of developmental delay, seizures and other neurological disease. However, a causal relationship between these events and NRTI exposure in utero or peri-partum has not been established. These findings do not affect current recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

Use in Lactation: A study in lactating rats showed that the concentration of lamivudine in milk, was more than four times higher than that in maternal plasma. Following oral administration lamivudine was excreted in human breast milk at similar concentrations to those found in serum (1 – 8 µg/mL). Since lamivudine and the virus pass into breast milk, it is recommended that mothers taking lamivudine do not breast feed their infants.

Effects on the Ability to Drive and Operate Machinery: There have been no studies to investigate the effect of lamivudine on driving performance or the ability to operate machinery. Further, a detrimental effect on such activities cannot be predicted from the pharmacology of the drug. Nevertheless, the clinical status of the patient and the adverse event profile of both

lamivudine and zidovudine should be borne in mind when considering the patient's ability to drive or operate machinery.

Patients should be advised that current antiretroviral therapy, including lamivudine, has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Appropriate precautions should continue to be employed.

Osteonecrosis: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.

INTERACTIONS WITH OTHER MEDICINES

The likelihood of interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged drug. Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim. Other drugs (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine.

Changes in zidovudine plasma levels when co-administered with lamivudine were not statistically significant. Zidovudine has no effect on the pharmacokinetics of lamivudine (see **PHARMACOKINETICS**).

Administration of trimethoprim, as trimethoprim/sulfamethoxazole 160 mg/800 mg increased lamivudine exposure by about 40%. However, unless the patient already has renal impairment, no dosage adjustment of lamivudine is necessary. Lamivudine has no effect on the pharmacokinetics of trimethoprim/sulfamethoxazole. Administration of lamivudine in patients with renal impairment should be assessed carefully. The effect of co-administration of lamivudine with higher doses of co-trimoxazole for the treatment of *Pneumocystis carinii* pneumonia and toxoplasmosis has not been studied.

In *in vitro* studies, ciprofloxacin, pentamidine and ganciclovir reduced the anti-HIV activity of lamivudine. The clinical significance of this is not known.

Lamivudine may inhibit the intracellular phosphorylation of zalcitabine when the two medicinal products are used concurrently. 3TC is therefore not recommended to be used in combination with zalcitabine.

ADVERSE EFFECTS:

Table 10 lists all adverse events, occurring at an incidence of 5% or more, reported in controlled pivotal clinical trials in adults, irrespective of the investigator's assessment of the possible relationship to the study drug.

Table 10 - Common adverse events (frequency $\geq 5.0\%$) reported in four pivotal, controlled clinical trials in adults

	ZDV	ZDV + LAM (150)	ZDV + LAM(300)	ZDV + DDC(0.75)
n=	230	251	318	86
BLOOD AND LYMPHATIC				
Lymphatic signs & symptoms	4.8	9.2	7.2	11.6
Decreased white cells	3.5	5.2	5.0	9.3
EAR NOSE AND THROAT				
Throat & tonsil discomfort & pain	9.6	9.2	11.6	14.0
Viral ear nose & throat infection	7.4	9.6	6.9	12.8
Ear nose & throat infection	7.0	10.8	11.3	12.8
Sinusitis	6.5	6.8	7.2	4.7
Upper respiratory inflammation	1.7	5.2	3.8	3.5
GASTROINTESTINAL				
Abdominal discomfort & pain	9.1	8.4	11.3	8.1
Fungal gastrointestinal infection	5.2	6.4	7.5	14.0
Gastrointestinal discomfort & pain	5.2	7.2	4.1	5.8
Gaseous symptoms	2.6	5.2	3.1	2.3
LOWER RESPIRATORY				
Bronchitis	4.8	10.0	4.7	5.8
Breathing disorders	3.5	5.6	4.1	3.5
MUSCULOSKELETAL				
Musculoskeletal pain	9.6	12.0	13.5	22.1
Muscle pain	5.7	8.4	3.5	11.6
NEUROLOGY				
Headache	27.0	35.1	28.9	33.7
Neuropathy	10.0	12.4	8.5	23.3
Sleep disorders	7.0	10.8	11.6	8.1
Dizziness	3.9	10.4	6.0	9.3
NON-SITE SPECIFIC				
Viral infection	4.3	7.6	6.6	20.9
SKIN				
Sweating	7.0	7.6	6.3	7.0
Fungal skin infection	6.1	5.6	4.1	7.0
Acne & folliculitis	3.9	6.8	3.5	11.6
Viral skin infection	3.5	5.2	4.7	7.0

Common laboratory abnormalities observed during therapy are listed in Table 11

Table 11 - Frequencies of common laboratory abnormalities in 4 pivotal, controlled clinical trials in adults*

Test (Abnormal Level)	lamivudine 150 mg b.i.d. Plus zidovudine % (n)	zidovudine % (n)
Neutropenia (ANC<750/mm ³)	7.2% (237)	5.4% (222)
Anaemia (Hb<8.0 g/dL)	2.9% (241)	1.8% (218)
Thrombocytopenia (platelets<50,000/mm ³)	0.4% (240)	1.3% (223)
ALT (>5.0 x ULN)	3.7% (241)	3.6% (224)
AST (>5.0 x ULN)	1.7% (241)	1.8% (223)
Bilirubin (>2.5 ULN)	0.8% (241)	0.4% (220)
Amylase (>2.0 ULN)	4.2% (72)	1.5% (133)

ULN = Upper limit of normal

ANC = absolute neutrophil count

n = Number of patients assessed

* Frequencies of these laboratory abnormalities were higher in patients with mild laboratory abnormalities at baseline.

Lamivudine appears to be well tolerated and most serious adverse events reported in clinical trials are not considered to be drug related. Adverse reactions from the 4 pivotal studies in adult patients receiving the recommended dose of lamivudine (150mg bd) in combination with zidovudine 600mg/day are included in table 12 together with serious adverse reactions reported in large scale open studies.

With many of these adverse reactions it is unclear whether they are drug-related or are a result of the underlying disease.

Table 12 - Adverse drug reactions reported in controlled trials and open studies

Adverse reactions reported in controlled clinical trials - (n= 251) Lamivudine 150mg bd + zidovudine 600mg/day	Serious adverse reactions reported in open studies (n= 17,572), Lamivudine 300mg bd (n=10,575), Lamivudine 150mg bd (n=6997), generally in combination with other antiretroviral therapy
Non-site specific <i>Very common</i> Malaise and fatigue <i>Common</i> Fever	Non-site specific <i>Rare</i> Malaise and fatigue, fever
Blood and Lymphatic <i>Common</i> Anaemia, Decreased white cells	Blood and Lymphatic <i>Uncommon</i> Decreased white cells <i>Rare</i> Anaemia Thrombocytopenia
Neurological <i>Very common</i> Headache <i>Common</i> Neuropathy	Neurological <i>Rare</i> Neuropathy Headaches Paraesthesia

Gastrointestinal <i>Very Common</i> Nausea <i>Common</i> Diarrhoea Discomfort and pain Vomiting	Gastrointestinal <i>Rare</i> Nausea and vomiting Abdominal discomfort and pain Diarrhoea
Hepatobiliary tract and pancreas <i>Common</i> Abnormal liver function tests <i>Uncommon</i> Pancreatitis	Hepatobiliary tract and pancreas <i>Uncommon</i> Pancreatitis <i>Rare</i> Abnormal pancreatic enzymes Abnormal liver function tests
Skin <i>Common</i> rashes	Skin <i>Very rare</i> rashes

Cases of pancreatitis have occurred rarely in adult patients and more commonly in children. However it is not clear whether these cases were due to drug treatment or to their underlying HIV disease. Treatment with lamivudine should be stopped immediately if clinical signs or symptoms or laboratory abnormalities suggestive of pancreatitis occur.

In paediatric patients with a history of pancreatitis or other significant risk factors for the development of pancreatitis, the combination of lamivudine with other antiretroviral therapies should be used with extreme caution and only if there is no satisfactory alternative therapy.

Pancreatitis, which has been fatal in some cases has been observed in paediatric patients receiving lamivudine alone or in combination with other antiretroviral agents. In an open-label dose-escalation study, 14 patients (14%) developed pancreatitis while receiving monotherapy with lamivudine. Three of these patients died of complications of pancreatitis. In a second open-label study, 12 patients (18%) developed pancreatitis. In both these open label studies, the paediatric subjects had advanced, symptomatic HIV infection and many had received extensive prior therapy. In addition, many of the children had predisposing medical conditions or medications which could have contributed to pancreatitis. In study ACTG300 in therapy-naïve subjects, pancreatitis was not observed in 236 patients randomised to lamivudine + zidovudine. Pancreatitis was observed in one patient in this study who received open-label lamivudine in combination with zidovudine and ritonavir following discontinuation of didanosine monotherapy. Paraesthesia and peripheral neuropathies were reported in 15 patients (15%) in one open study and 6 patients (9%) in the other open study and in 2 patients (1%) in ACTG300.

Table 13 lists all the adverse events, occurring at an incidence of 5% or more, reported in study EPV 20001

Table 13: Adverse Events (frequency \geq 5%) in Study EPV 20001

BODY SYSTEM Event	3TC (OD) (N=272)		3TC (BD) (N=273)	
Subjects With Any Event	251	(92%)	263	(96%)
Nausea	103	(38%)	115	(42%)
Dizziness	78	(29%)	96	(35%)
Fatigue	78	(29%)	76	(28%)
Dreams	70	(26%)	63	(23%)
Rashes	62	(23%)	49	(18%)
Headaches	61	(22%)	49	(18%)
Diarrhoea	50	(18%)	48	(18%)
Sleep disorders	43	(16%)	44	(16%)
Viral respiratory infections	41	(15%)	37	(14%)
Vomiting	31	(11%)	41	(15%)
Ear nose & throat infections	25	(9%)	37	(14%)
Anorexia	33	(12%)	22	(8%)
Mood disorders	30	(11%)	23	(8%)
Abdominal pain	22	(8%)	28	(10%)
Hypnagogic effects	19	(7%)	23	(8%)
Musculoskeletal pain	16	(6%)	24	(9%)
Fever	13	(5%)	26	(10%)
Dyspeptic symptoms	17	(6%)	19	(7%)
Fungal skin infections	18	(7%)	17	(6%)
Sinus disorders	14	(5%)	21	(8%)
Depressive disorders	12	(4%)	22	(8%)
Anxiety	15	(6%)	16	(6%)
Throat signs & symptoms	14	(5%)	16	(6%)
Cough	13	(5%)	16	(6%)
Pruritus	16	(6%)	12	(4%)
Sweating	11	(4%)	17	(6%)
Increased liver function tests	11	(4%)	13	(5%)
Decreased white cells	9	(3%)	14	(5%)
Taste disorders	9	(3%)	14	(5%)
Abdominal discomfort	8	(3%)	14	(5%)
Paresthesia peripheral	13	(5%)	9	(3%)
Anaemia	4	(1%)	14	(5%)

Table 14: Treatment emergent Grade 3 / 4 Laboratory Abnormalities (frequency $\geq 2\%$) in Study EPV 20001

Laboratory Parameter	OD N=272 n (%)			BD N=273 n (%)		
	Grade 3	Grade 4	Grade 3/4	Grade 3	Grade 4	Grade 3/4
Clinical Chemistry						
Increased ALT	5 (2)	3 (1)	8 (3)	6 (2)	5 (2)	11 (4)
Hypertriglyceridemia	8 (3)	2 (<1)	10 (4)	4 (1)	0	4 (1)
Increased AST	2 (<1)	2 (<1)	4 (1)	6 (2)	2 (<1)	8 (3)
Hyperamylasemia	7 (3)	0	7 (3)	2 (<1)	0	2 (<1)
Hematology Neutropenia	8 (3)	4 (1)	12 (4)	10 (4)	6 (2)	19 (6)

The data from the clinical trials have shown no significant difference in the frequency or severity of unwanted effects between administration of 150mg twice daily and 300mg once daily. There was however a higher incidence of hyperamylasaemia in the once daily regimen.

Adverse Events & laboratory findings in study ACTG300 are provided in Tables 15 & 16.

Table 15: Selected Clinical Adverse Events and Physical Findings (≥5% Frequency) in Pediatric Patients in Study ACTG300

Adverse Event	EPIVIR plus RETROVIR (n = 236)	Didanosine (n = 236)
Body as a whole		
Fever	58 (25%)	75 (32%)
Digestive		
Hepatomegaly	25 (11%)	25 (11%)
Nausea & vomiting	18 (8%)	16 (7%)
Diarrhea	18 (8%)	15 (6%)
Stomatitis	13 (6%)	28 (12%)
Splenomegaly	12 (5%)	18 (8%)
Respiratory		
Cough	36 (15%)	34 (18%)
Abnormal breath sounds/wheezing	16 (7%)	21 (9%)
Ear, Nose, and Throat		
Signs or symptoms of ears*	16 (7%)	13 (6%)
Nasal discharge or congestion	18 (8%)	25 (11%)
Other		
Skin rashes	24 (12%)	32 (14%)
Lymphadenopathy	22 (9%)	27 (11%)

*Includes pain, discharge, erythema, or swelling of an ear.

Selected laboratory abnormalities experienced by therapy-naïve (≤56 days of antiretroviral therapy) pediatric patients are listed in Table 16.

Table 16: Frequencies of Selected Laboratory Abnormalities in Pediatric Patients in Study ACTG300

Test (Abnormal Level)	EPIVIR plus RETROVIR	Didanosine
Neutropenia (ANC<400/mm ³)	18 (8%)	8 (3%)
Anemia (Hgb<7.0 g/dL)	9 (4%)	5 (2%)
Thrombocytopenia (platelets<50,000/mm ³)	3 (1%)	6 (3%)
ALT (>10 x ULN)	3 (1%)	8 (3%)
AST (>10 x ULN)	4 (2%)	9 (4%)
Lipase (>2.5 x ULN)	6 (3%)	6 (3%)
Total Amylase (>2.5 x ULN)	6 (3%)	6 (3%)

ULN = Upper limit of normal.

ANC = Absolute neutrophil count.

Post-Marketing Data :

The following events have been reported during therapy for HIV disease with lamivudine alone and in combination with other anti-retroviral agents.

Musculoskeletal:- arthralgia, muscle disorders including rarely rhabdomyolysis.

Skin - alopecia (rare)

Haematological – pure red cell aplasia.

Metabolism and nutrition disorders

Hyperlactataemia (common)

Lactic acidosis (rare, see Precautions)

Redistribution/accumulation of body fat (**SEE PRECAUTIONS**). The incidence of this event is dependent on multiple factors including the particular antiretroviral drug combination.

DOSAGE AND ADMINISTRATION:

Food reduces the C_{max} and extends the T_{max} but the amount of drug absorbed is not reduced. The clinical significance of this is not known (see **PHARMACOKINETICS**)

Clinical studies indicate that 3TC should be used in combination with other antiretroviral therapies. In controlled trials in adults, 3TC was used in combination with zidovudine 200 mg tds (see **CLINICAL TRIALS**)

Since accurate dosing can not be achieved with this formulation, dosing according to weight bands is recommended for scored tablets. This dosing regimen for paediatric patients weighing 14 - 30 kg is based primarily on pharmacokinetic modelling. Therefore monitoring of efficacy and safety is necessary in these patients. More accurate dosing can be achieved with oral solution of lamivudine.

To ensure administration of the entire dose, the tablet(s) should ideally be swallowed without crushing. For patients who are unable to swallow tablets, the tablets may be crushed and 100% of the crushed tablets could be added to a small amount of semi-solid food or liquid, all of which should be consumed immediately (see Pharmacokinetics). Alternatively, lamivudine is available as an oral solution.

Adults and adolescents weighing at least 30kg:

Tablets

The recommended dose of 3TC is 150 mg twice daily. Alternatively, it may be administered as 300 mg once daily in patients who may benefit from a once daily regimen. (See **Clinical Trial Section**)

Oral Solution

The recommended dose is 3TC 150 mg (15 mL) twice daily.

Children less than three months of age:

The limited data available are insufficient to propose specific dosage recommendations (see **CLINICAL TRIALS** and **PHARMACOKINETICS**).

For children aged greater than three months and weighing less than 30kg:

Oral Solution

The recommended dose of 3TC is 4 mg/kg twice daily up to a maximum of 300 mg (30 mL) daily.

Tablets

For children weighing between 21 kg to 30 kg:-

The recommended oral dose of Lamivudine (150 mg) is one-half tablet taken in the morning and one whole tablet taken in the evening.

Children weighing 14 to 21 kg: -

The recommended oral dose of Lamivudine (150 mg) is one half of a scored tablet taken twice daily.

Lamivudine is also available as an oral solution for children who weigh less than 14 kg or who are unable to swallow tablets.

Renal Impairment: Lamivudine plasma concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased clearance. The dose should therefore be adjusted (see tables 17, 18 & 19). Insufficient data are available to recommend a dosage of lamivudine in paediatric patients with renal impairment. A reduction in the dose and/or an increase in the dosing interval should be considered.

Table 17 - Dosing recommendations – Adults and adolescents weighing at least 30kg:

Oral solution	
Creatinine Clearance (mL/min)	Recommended Dosage of Lamivudine
≥ 50	150 mg (15 mL) twice daily
30-49	150 mg (15 mL) once daily
15-29	150 mg (15 mL) first dose, then 100 mg (10 mL) once daily
5-14	150 mg (15mL) first dose, then 50 mg (5 mL) once daily
< 5	50 mg (5mL) first dose, then 25 mg (2.5 mL) once daily

Table 18 - Dosing recommendations – Children ≥ 3 months and weighing less than 30kg:

Oral solution	
Creatinine Clearance (mL/min)	Recommended Dosage of Lamivudine
≥ 50	4 mg/Kg twice daily
30-49	4 mg/Kg once daily
15-29	4 mg/Kg first dose, then 2.6 mg/Kg once daily
5-14	4 mg/Kg first dose, then 1.3 mg/Kg once daily
< 5	1.3 mg/Kg first dose, then 0.7 mg/Kg once daily

Table 19 - Dosing recommendations – Adults and adolescents >12 years of age

Tablets	
Creatinine Clearance (mL/min)	Recommended Dosage of Lamivudine
≥50	150 mg twice daily
30-49	150 mg once daily
<30	As doses below 150 mg are needed the use of the oral solution is recommended.

Intermittent dialysis is unlikely to require further dose modification from that defined by creatinine clearance.

Hepatic Impairment:

Data obtained in patients with moderate to severe hepatic impairment shows that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction. Based on these data, no dose adjustment is necessary in patients with moderate or severe hepatic impairment unless accompanied by renal impairment.

OVERDOSAGE:

Administration of lamivudine at very high dose levels in acute animal studies did not result in any organ toxicity. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied.

Treatment of overdose should be symptomatic and consist of general supportive measures. Contact the Poisons Information Centre on 13 11 26 for advice on management of overdose.

PRESENTATION AND STORAGE CONDITIONS:**Tablets:**

3TC tablets are supplied in a white, high-density polyethylene (HDPE) bottle with a plastic cap. The bottle of 3TC 150 mg tablets contains 60 tablets and the bottle of 3TC 300 mg tablets contains 30 tablets. Each bottle is in a carton.

3TC 150mg Tablets are available as both scored and unscored tablets.

3TC 150 mg unscored tablets are white, film-coated, diamond-shaped tablets, engraved 'GX CJ7' on the upper tablet face. Each tablet contains 150 mg of lamivudine.

3TC 150 mg scored tablets are white, film-coated, diamond-shaped tablets, engraved 'GX CJ7' on both tablet faces. Each tablet contains 150 mg of lamivudine.

3TC 300 mg tablets are grey, film-coated, diamond-shaped, engraved 'GX EJ7' on the upper tablet face. Each tablet contains 300 mg of lamivudine.

3TC tablets also contain microcrystalline cellulose (460), sodium starch glycollate, magnesium stearate (572), hypromellose (464), titanium dioxide (171), macrogol 400, polysorbate 80 (433) and purified water. The 300 mg tablets also contain black iron oxide (E172).

Store below 30°C.

Oral Solution:

3TC oral solution is supplied in a white HDPE bottle, with a plastic cap. The bottle contains 240 mL of 3TC solution, for oral use only, and is in a carton.

3TC oral solution contains 10 mg/mL lamivudine and 20% (w/v) sucrose.

3TC oral solution also contains methyl hydroxybenzoate (218), propyl hydroxybenzoate (216), citric acid anhydrous, sodium citrate, propylene glycol, artificial strawberry flavouring, artificial banana flavouring and purified water.

Store below 25°C.

Not all strengths, dose forms and pack sizes may be distributed in Australia.

NAME AND ADDRESS OF THE SPONSOR:

ViiV Healthcare Pty Ltd
Level 4
436 Johnston St,
Abbotsford, Victoria, 3067
Australia

POISON SCHEDULE OF THE MEDICINE: S4

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (the ARTG): 13 March 1996

DATE OF MOST RECENT AMENDMENT: 19 June 2012

3TC[®] and **Retrovir[®]** are registered trade marks of the ViiV Healthcare group of companies.

Version 4.0